跳至主要内容
临床试验/EUCTR2014-000096-80-GB
EUCTR2014-000096-80-GB进行中(未招募)1 期

Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST) - TWIST

niversity or Tromsø0 个研究点目标入组 500 人开始时间: 2016年7月5日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Stroke symptoms on awakening that were not present before sleep
  • Clinical diagnosis of stroke with limb weakness with NIHSS score >5, or dysphasia.
  • Treatment with tenecteplase is possible within 4.5 hours of awakening
  • Written consent from the patient, non-written consent from the patient (witnessed by non-participating health care personnel), or written consent from the nearest family member.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 100
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 400

排除标准

  • Age < 18 years
  • Findings on plain CT that indicate that the patient is unlikely to benifit from treatment:
  • -Infarction comprising more than >1/3 of the middle cerebral artery territory on plain CT
  • -Intracranial haemorrhage, structural brain lesions which can mimic stroke (e.g cerebral tumour)
  • Patient will be treated with intra-arterial interventions for proximal cerebral artery occlusion
  • High risk of bleeding, e.g.:
  • -Major surgery, trauma or gastrointestinal or urinary tract haemorrhage within the previous 21 days, or arterial puncture at a non-compressible site within the previous 7 days.
  • -Any known defect in coagulation, e.g. current use of vitamin K antagonist with an INR > 1.7, or other oral anticoagulant, or heparins
  • -Known defect of clotting or platelet function (but patients on antiplatelet agents can be included)
  • -Ischaemic stroke in previous 2 weeks, previous intracranial haemorrhage, or known arteriovenous malformation or aneurysm
  • Persistent blood pressure elevation (systolic =185 mmHg or diastolic =110 mmHg), despite blood pressure lowering treatment
  • Blood glucose < 3.0 or > 20.0 mmol/L
  • Childbearing potential, pregnancy, positive pregnancy test, breastfeeding
  • Other serious or life-threatening disease before the stroke: severe mental or physical disability (e.g. Mini Mental Status score < 20, or modified Rankin Scale score = 3), or life expectancy less than 12 months
  • Patient unavailability for follow-up (e.g. no fixed address)

研究者

发起方
niversity or Tromsø

相似试验

Study of clot dissolving treatment for stroke that... | 临床试验